AKR1B1 As a Prognostic Biomarker of High-Grade Serous Ovarian Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Feb 15

PMID 35159076

Authors

Marko Hojnik

Natasa Kenda Suster

Spela Smrkolj

Damjan Sisinger

Snjezana Frkovic Grazio

Ivan Verdenik

Tea Lanisnik Rizner

Affiliations

Soon will be listed here.

Abstract

Although aldo-keto reductases (AKRs) have been widely studied in cancer, no study to date has examined the roles of AKR family 1 members B1 (AKR1B1) and B10 (AKR1B10) in a large group of ovarian cancer patients. AKR1B1 and AKR1B10 play a significant role in inflammation and the metabolism of different chemotherapeutics as well as cell differentiation, proliferation, and apoptosis. Due to these functions, we examined the potential of AKR1B1 and AKR1B10 as tissue biomarkers. We assessed the immunohistochemical levels of AKR1B1 and AKR1B10 in tissue paraffin sections from 99 patients with high-grade serous ovarian cancer (HGSC) and compared these levels with clinicopathological characteristics, survival, and response to chemotherapy. A higher immunohistochemical AKR1B1 expression correlated with a better overall and disease-free survival of HGSC patients whereas AKR1B10 expression did not show any significant differences. A multivariant Cox analysis demonstrated that a high AKR1B1 expression was an important prognostic factor for both overall and disease-free survival. However, AKR1B1 and AKR1B10 were not associated with different responses to chemotherapy. Our data suggest that AKR1B1 is involved in the pathogenesis of HGSC and is a potential prognostic biomarker for this cancer.

Citing Articles

Analysis of ATP7A Expression and Ceruloplasmin Levels as Biomarkers in Patients Undergoing Neoadjuvant Chemotherapy for Advanced High-Grade Serous Ovarian Carcinoma.

Lukanovic D, Polajzer S, Matjasic M, Kobal B, cerne K Int J Mol Sci. 2024; 25(18).

PMID: 39337685 PMC: 11432368. DOI: 10.3390/ijms251810195.

AKR1B10 inhibits the proliferation and metastasis of hepatocellular carcinoma cells by regulating the PI3K/AKT pathway.

Tian K, Deng Y, Li Z, Zhou H, Yao H Oncol Lett. 2023; 27(1):18.

PMID: 38034486 PMC: 10688483. DOI: 10.3892/ol.2023.14151.

Aberrant expression of AKR1B1 indicates poor prognosis and promotes gastric cancer progression by regulating the AKT-mTOR pathway.

Liu L, Zhu L, Cheng Z, Sun Y, Zhou Y, Cao J Aging (Albany NY). 2023; 15(18):9661-9675.

PMID: 37751590 PMC: 10564407. DOI: 10.18632/aging.205041.

AKR1B1 Represses Glioma Cell Proliferation through p38 MAPK-Mediated Bcl-2/BAX/Caspase-3 Apoptotic Signaling Pathways.

Huang Y, Chang K, Li C, Lieu A, Lin C Curr Issues Mol Biol. 2023; 45(4):3391-3405.

PMID: 37185746 PMC: 10136867. DOI: 10.3390/cimb45040222.

Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer.

Gyorffy B Geroscience. 2023; 45(3):1889-1898.

PMID: 36856946 PMC: 10400493. DOI: 10.1007/s11357-023-00742-4.

References

Hojnik M, Grazio S, Verdenik I, Rizner T . AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas. Cancers (Basel). 2021; 13(14). PMC: 8305663. DOI: 10.3390/cancers13143398. View

Matulonis U, Sood A, Fallowfield L, Howitt B, Sehouli J, Karlan B . Ovarian cancer. Nat Rev Dis Primers. 2016; 2:16061. PMC: 7290868. DOI: 10.1038/nrdp.2016.61. View

Hofman J, Malcekova B, Skarka A, Novotna E, Wsol V . Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3. Toxicol Appl Pharmacol. 2014; 278(3):238-48. DOI: 10.1016/j.taap.2014.04.027. View

Torres-Mena J, Salazar-Villegas K, Sanchez-Rodriguez R, Lopez-Gabino B, Del Pozo-Yauner L, Arellanes-Robledo J . Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC. Dig Dis Sci. 2018; 63(4):934-944. DOI: 10.1007/s10620-018-4943-5. View

Mounier C, Bouraoui L, Rassart E . Lipogenesis in cancer progression (review). Int J Oncol. 2014; 45(2):485-92. DOI: 10.3892/ijo.2014.2441. View

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

Reddy K, Uday Kumar P, Srinivasulu M, Triveni B, Sharada K, Ismail A . Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancers. Breast. 2016; 31:137-143. DOI: 10.1016/j.breast.2016.11.003. View

Jung K, Choi B, Nam C, Song M, Kim S, Lee J . Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Toxicol Lett. 2013; 218(1):39-49. DOI: 10.1016/j.toxlet.2012.12.026. View

Deng H, Parekh H, Chow K, Simpkins H . Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem. 2002; 277(17):15035-43. DOI: 10.1074/jbc.M112028200. View

10.

Penning T . The aldo-keto reductases (AKRs): Overview. Chem Biol Interact. 2014; 234:236-46. PMC: 4388799. DOI: 10.1016/j.cbi.2014.09.024. View

11.

Yao Y, Wang X, Zhou D, Li H, Qian H, Zhang J . Loss of AKR1B10 promotes colorectal cancer cells proliferation and migration via regulating FGF1-dependent pathway. Aging (Albany NY). 2020; 12(13):13059-13075. PMC: 7377871. DOI: 10.18632/aging.103393. View

12.

Asangani I, Blair I, Van Duyne G, Hilser V, Moiseenkova-Bell V, Plymate S . Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer. J Biol Chem. 2021; 296:100240. PMC: 7949100. DOI: 10.1074/jbc.REV120.012411. View

13.

Singh M, Kapoor A, Bhatnagar A . Oxidative and reductive metabolism of lipid-peroxidation derived carbonyls. Chem Biol Interact. 2015; 234:261-73. PMC: 4414726. DOI: 10.1016/j.cbi.2014.12.028. View

14.

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

15.

Demirkol Canli S, Seza E, Sheraj I, Gomceli I, Turhan N, Carberry S . Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway. Carcinogenesis. 2020; 41(9):1219-1228. DOI: 10.1093/carcin/bgaa072. View

16.

DiStefano J, Davis B . Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma. Cancers (Basel). 2019; 11(4). PMC: 6521254. DOI: 10.3390/cancers11040486. View

17.

Matsunaga T, Suzuki A, Kezuka C, Okumura N, Iguchi K, Inoue I . Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism. Chem Biol Interact. 2016; 256:142-53. DOI: 10.1016/j.cbi.2016.07.008. View

18.

Zhang X, Hong S, Zhang M, Cai Q, Zhang M, Xu C . Proteomic alterations of fibroblasts induced by ovarian cancer cells reveal potential cancer targets. Neoplasma. 2017; 65(1):104-112. DOI: 10.4149/neo_2018_101. View

19.

Ashworth A . Drug resistance caused by reversion mutation. Cancer Res. 2008; 68(24):10021-3. DOI: 10.1158/0008-5472.CAN-08-2287. View

20.

Hojnik M, Kenda Suster N, Smrkolj S, Grazio S, Verdenik I, Rizner T . AKR1C3 Is Associated with Better Survival of Patients with Endometrial Carcinomas. J Clin Med. 2020; 9(12). PMC: 7766127. DOI: 10.3390/jcm9124105. View